SPARC is dispensable for murine hematopoiesis, despite its suspected pathophysiological role in 5q-myelodysplastic syndrome

Leukemia

Volumn 26, Issue 11, 2012, Pages 2416-2419

  Siva, K ^a   Jaako, P ^a   Miharada, K ^a   Rorby E ^a   Ehinger, M ^b   Karlsson, G ^a   Karlsson, S ^a  

^a Lund Strategic Center for Stem Cell Biology   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEONECTIN; REGULATOR PROTEIN;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; BONE REMODELING; CELL DIFFERENTIATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LETTER; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEADY STATE; THROMBOCYTOPENIA;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 5; HUMANS; MICE; MICE, KNOCKOUT; MYELODYSPLASTIC SYNDROMES; OSTEONECTIN;

EID: 84869086200     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.97     Document Type: Letter

References (15)

1. Bruno L, Hoffmann R, McBlane F, Brown J, Gupta R, Joshi C et al. Molecular signatures of self-renewal, differentiation, and lineage choice in multipotential hemopoietic progenitor cells in vitro. Mol Cell Biol 2004; 24: 741-756. (Pubitemid 38057925)
2. Eckfeldt CE, Mendenhall EM, Flynn CM, Wang TF, Pickart MA, Grindle SM et al. Functional analysis of human hematopoietic stem cell gene expression using zebrafish. PLoS Biol 2005; 3: E254.
3. Lehmann S, O'Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. Common deleted genes in the 5q- syndrome: Thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia 2007; 21: 1931-1936. (Pubitemid 47299966)
4. DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y et al. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 2006; 20: 426-432. (Pubitemid 43291739)
5. Yan Q, Sage EH. SPARC a matricellular glycoprotein with important biological functions. J Histochem Cytochem 1999; 47: 1495-1506.
6. Gilmour DT, Lyon GJ, Carlton MB, Sanes JR, Cunningham JM, AnDerson JR et al. Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens. EMBO J 1998; 17: 1860-1870. (Pubitemid 28154517)
7. Norose K, Clark JI, Syed NA, Basu A, Heber-Katz E, Sage EH et al. SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci 1998; 39: 2674-2680. (Pubitemid 28558226)
8. Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL et al. A p53-dependent mechanism unDerlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010; 16: 59-66.
9. Pronk CJ, Rossi DJ, Mansson R, Attema JL, Norddahl GL, Chan CK et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell 2007; 1: 428-442. (Pubitemid 47506534)
10. Brun AC, Bjornsson JM, Magnusson M, Larsson N, Leveen P, Ehinger M et al. Hoxb4-deficient mice unDergo normal hematopoietic development but exhibit a mild proliferation defect in hematopoietic stem cells. Blood 2004; 103: 4126-4133. (Pubitemid 38685353)
11. Delany AM, Hankenson KD. Thrombospondin-2 and SPARC/osteonectin are critical regulators of bone remodeling. J Cell Commun Signal 2009; 3: 227-238.
12. Pellagatti A, JaDersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007; 104: 11406-11411. (Pubitemid 47175153)
13. Tai IT, Tang MJ. SPARC in cancer biology: Its role in cancer progression and potential for therapy. Drug Resist Updat 2008; 11: 231-246.
14. Lane SW, De Vita S, AlexanDer KA, Karaman R, Milsom MD, Dorrance AM et al. Rac signaling in osteoblastic cells is required for normal bone development but is dispensable for hematopoietic development. Blood 2012; 119: 736-744.
15. Miyamoto K, Yoshida S, Kawasumi M, Hashimoto K, Kimura T, Sato Y et al. Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J Exp Med 2011; 208: 2175-2181.